LeMaitre Vascular (NASDAQ:LMAT) Releases FY 2024 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) updated its FY 2024 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 1.730-1.840 for the period, compared to the consensus estimate of 1.650. The company issued revenue guidance of $212.7 million-$217.3 million, compared to the consensus revenue estimate of $211.7 million. LeMaitre Vascular also updated its Q2 2024 guidance to 0.450-0.500 EPS.

LeMaitre Vascular Price Performance

NASDAQ:LMAT opened at $74.22 on Monday. The company has a fifty day moving average price of $65.93 and a 200 day moving average price of $58.85. The stock has a market cap of $1.67 billion, a P/E ratio of 49.15, a PEG ratio of 2.99 and a beta of 0.88. LeMaitre Vascular has a one year low of $44.27 and a one year high of $74.64.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.05. LeMaitre Vascular had a return on equity of 11.57% and a net margin of 16.99%. The firm had revenue of $53.48 million for the quarter, compared to analysts’ expectations of $51.50 million. During the same period in the prior year, the business posted $0.27 earnings per share. The business’s revenue was up 13.6% compared to the same quarter last year. As a group, equities research analysts anticipate that LeMaitre Vascular will post 1.77 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 30th. Investors of record on Thursday, May 16th will be given a dividend of $0.16 per share. The ex-dividend date is Wednesday, May 15th. This represents a $0.64 annualized dividend and a yield of 0.86%. LeMaitre Vascular’s dividend payout ratio (DPR) is 42.38%.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on LMAT shares. StockNews.com raised shares of LeMaitre Vascular from a hold rating to a buy rating in a research note on Friday. JMP Securities increased their price objective on LeMaitre Vascular from $72.00 to $77.00 and gave the stock a market outperform rating in a research report on Friday. Barrington Research raised their price objective on LeMaitre Vascular from $69.00 to $79.00 and gave the stock an outperform rating in a research note on Friday. KeyCorp began coverage on shares of LeMaitre Vascular in a research note on Tuesday, February 6th. They issued a sector weight rating on the stock. Finally, Stifel Nicolaus raised shares of LeMaitre Vascular from a hold rating to a buy rating and increased their target price for the stock from $59.00 to $75.00 in a report on Friday, April 26th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, LeMaitre Vascular presently has an average rating of Moderate Buy and an average target price of $73.83.

Insider Buying and Selling

In other LeMaitre Vascular news, Director Lawrence J. Jasinski sold 5,110 shares of the firm’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $67.50, for a total value of $344,925.00. Following the completion of the sale, the director now owns 5,309 shares of the company’s stock, valued at $358,357.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Lawrence J. Jasinski sold 5,110 shares of LeMaitre Vascular stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $67.50, for a total transaction of $344,925.00. Following the transaction, the director now owns 5,309 shares of the company’s stock, valued at $358,357.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO George W. Lemaitre sold 27,859 shares of the company’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $69.73, for a total value of $1,942,608.07. Following the completion of the transaction, the chief executive officer now directly owns 2,255,737 shares of the company’s stock, valued at $157,292,541.01. The disclosure for this sale can be found here. Insiders have sold a total of 114,036 shares of company stock valued at $7,873,749 over the last ninety days. 10.79% of the stock is owned by corporate insiders.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.